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Abstract: Objectives
Prevalence of Lewy body dementias (LBD) is second only to Alzheimer's disease (AD)
among people with neurodegenerative dementia. LBD cause earlier mortality, more
intense neuropsychiatric symptoms, more caregivers’ burden, and higher costs than
AD. The molecular mechanisms underlying LBD are largely unknown. As advancing
molecular level mechanistic understanding is essential for identifying reliable peripheral
biomarkers and novel therapeutic targets for LBD, we aimed to identify differentially
expressed genes (DEG), and dysfunctional molecular networks in post-mortem LBD
brains.
Methods
We investigated the transcriptomics of post-mortem anterior cingulate and dorsolateral
prefrontal cortices of people with pathology-verified LBD using next-generation RNA-
sequencing. We verified the identified DEG using high-throughput quantitative
polymerase chain reactions. Functional implications of identified DEG, and the
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consequent metabolic reprogramming were evaluated by Ingenuity pathway analyses,
genome-scale metabolic modelling, reporter metabolite analyses, and in-silico gene
silencing.
Results
We identified and verified 12 novel DEGs (MPO, SELE, CTSG, ALPI, ABCA13,
GALNT6, SST, RBM3, CSF3, SLC4A1, OXTR, and RAB44) in LBD brains with
genome-wide statistical significance. We documented statistically significant
downregulation of several cytokine genes. Identified dysfunctional molecular networks
highlighted the contributions of mitochondrial dysfunction, oxidative stress, and
immunosenescence towards neurodegeneration in LBD.
Conclusion
Our findings support that chronic microglial activation and neuroinflammation, well-
documented in AD, are notably absent in LBD. The lack of neuroinflammation in LBD
brains were corroborated by statistically significant downregulation of several
inflammatory markers. Identified DEGs, especially downregulated inflammatory
markers, may aid distinguishing LBD from AD, and their biomarker potential warrant
further investigation.
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Highlights 
 
What is the primary question addressed by this study? 
 What are the differentially expressed genes and dysfunctional molecular networks in 
post-mortem brains of people with Lewy body dementia (LBD)? 
 
What is the main finding of this study? 
 This study has identified and verified 12 novel differentially expressed genes in LBD 
brains. Downregulation of several inflammatory markers revealed the absence of chronic 
neuroinflammation in LBD. 
 
What is the meaning of the finding? 
 The findings advance molecular level mechanistic understanding and indicate potential 
biomarkers for LBD that warrant further investigation. 
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Abstract: 
Objectives: Prevalence of Lewy body dementias (LBD) is second only to Alzheimer's disease 
(AD) among people with neurodegenerative dementia. LBD cause earlier mortality, more 
intense neuropsychiatric symptoms, more caregivers’ burden, and higher costs than AD. The 
molecular mechanisms underlying LBD are largely unknown. As advancing molecular level 
mechanistic understanding is essential for identifying reliable peripheral biomarkers and novel 
therapeutic targets for LBD, we aimed to identify differentially expressed genes (DEG), and 
dysfunctional molecular networks in post-mortem LBD brains. 
Methods: We investigated the transcriptomics of post-mortem anterior cingulate and 
dorsolateral prefrontal cortices of people with pathology-verified LBD using next-generation 
RNA-sequencing. We verified the identified DEG using high-throughput quantitative 
polymerase chain reactions. Functional implications of identified DEG, and the consequent 
metabolic reprogramming were evaluated by Ingenuity pathway analyses, genome-scale 
metabolic modelling, reporter metabolite analyses, and in-silico gene silencing.  
Results: We identified and verified 12 novel DEGs (MPO, SELE, CTSG, ALPI, ABCA13, 
GALNT6, SST, RBM3, CSF3, SLC4A1, OXTR, and RAB44) in LBD brains with genome-wide 
statistical significance. We documented statistically significant downregulation of several 
cytokine genes. Identified dysfunctional molecular networks highlighted the contributions of 
mitochondrial dysfunction, oxidative stress, and immunosenescence towards 
neurodegeneration in LBD.  
Conclusion: Our findings support that chronic microglial activation and neuroinflammation, 
well-documented in AD, are notably absent in LBD. The lack of neuroinflammation in LBD 
brains were corroborated by statistically significant downregulation of several inflammatory 
markers. Identified DEGs, especially downregulated inflammatory markers, may aid 
distinguishing LBD from AD, and their biomarker potential warrant further investigation.  
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Introduction: 
 Lewy body dementia (LBD) is a major public health problem worldwide. Prevalence 
of Lewy body dementia (LBD) is second only to Alzheimer’s disease (AD) among people with 
neurodegenerative dementia (1). LBD cause earlier mortality (2), earlier nursing home 
admissions, poorer quality-of-life, higher costs (3), more frequent falls, and more caregivers’ 
burden than AD. LBD include two overlapping clinical syndromes, dementia with Lewy bodies 
(DLB) and Parkinson’s disease (PD) dementia (PDD). They cause more frequent and more 
intense neuropsychiatric symptoms including visual hallucinations, delusions, agitation, and 
depression than AD (4). Antipsychotic medications should be avoided in all people with 
dementia whenever possible, and there is an urgent clinical need for diagnosing LBD early, 
because treating neuropsychiatric symptoms, common in LBD, with any antipsychotic 
medication risks potentially fatal adverse effects in people with LBD (5). However, the 
molecular mechanisms underlying neurodegeneration in LBD remain largely unknown, and 
prior research that focused mainly on known AD and PD biomarkers have not identified any 
reliable genetic markers for LBD (6). Moreover, there are no disease-modifying treatment for 
LBD (7). Hence, advancing molecular level mechanistic understanding is urgently needed for 
facilitating discovery of multimodal biomarkers and novel therapeutic targets for LBD (7,8).  
 A few candidate-gene association studies and a genome-wide association study 
(GWAS) have associated LBD with polymorphisms in APOE, SNCA, GBA, STX1B, GABRB3, 
CNTN1, and SCARB2 (9-11), but they could not ascertain functional implications of identified 
genetic associations. As a definite DLB diagnosis can be confirmed only by post-mortem (12), 
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genetic studies investigating people living with LBD are prone for misclassification bias. 
Hence, transcriptomic studies that identify differentially expressed ribonucleic acids (RNA) in 
post-mortem LBD brains are essential for understanding functionally relevant gene expression 
changes, and their dysfunctional molecular networks (13-15). Moreover, further research on 
the transcriptomics of LBD brains is needed for clarifying their neuroimmunology. Chronic 
microglial activation and neuroinflammation contribute to neurodegeneration in AD (16), but 
recent immunohistochemical studies have documented absence of neuroinflammation in LBD 
(17,18). Immunosenescence and consequent impaired neuronal survival are hypothesized to 
contribute to LBD pathology (17,18). Hence, we aimed to identify differentially expressed 
genes (DEG), dysfunctional molecular networks, and metabolic reprogramming in post-
mortem anterior cingulate (ACC), and dorsolateral prefrontal (DLPFC) cortices of people with 
pathology-verified LBD.  
Methods:  
Post-mortem brain tissue:  
 The Brains for Dementia Research (BDR) network of brain banks (19), UK, provided 
necessary post-mortem brain tissue, and ethical approval for this study. We obtained frozen 
sections of ACC (Brodmann area 24), and DLPFC (Brodmann area 9) of people with 
pathology-verified DLB (n=7), PDD (n=7), and of older people without dementia or PD (NDC) 
(n=7). The groups did not differ significantly on their age (F=0.88;df=2,18;p=0.43), and on 
their post-mortem intervals (F=0.04;df=2,18;p=0.96). We could not get ACC tissue of one 
person with DLB, and DLPFC tissue of one NDC person was not available (Supplemental 
digital content (SDC)-1). ACC is known to have high levels of Lewy body pathology in LBD 
(15), and Lewy body densities in ACC can predict cognitive impairment in PD (20). People 
with DLB have greater impairment of executive functions, regulated by DLPFC, than people 
with AD (21). Hence, we investigated the transcriptomics of these two cortical regions. 
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RNA extraction:  
 50mg of brain tissue per sample were excised on dry ice. Excised tissue was 
homogenized using the T10-basic ultra-turrax, and disposable dispersing element S10D-7G-
KS-110 (Ika works, Wilmington, USA). Total RNA was extracted using the RNeasy plus 
universal mini kit (Qiagen, Hilden, Germany). Quantity and quality of RNA were assessed 
using the NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, USA). Mean 260/280 and 
260/230 spectrophotometer absorbance ratios of purified RNA were 2.06 (95%CI 2.05-2.07), 
and 1.56 (95%CI 1.48-1.64), respectively.  
Next-generation RNA-sequencing (RNA-Seq):  
 cDNA libraries were prepared from RNA samples using TruSeq RNA sample 
preparation kit (Illumina, San Diego, USA). The cDNA libraries underwent paired-end 
sequencing (75 base pairs/read) using the Illumina HiSeq-4000 (Illumina, San Diego, USA) in 
the Wellcome Centre for Human Genetics (WHG), Oxford, UK. We obtained a minimum of 
30 million clean reads/sample. 
RNA-Seq data analyses:  
 RNA-Seq reads passed quality control, if they did not include any ambiguous bases, 
and if more than 90% of bases had less than 1% sequencing error. Such reads were aligned to 
the human genome (Homo_sapiens.GRCh38) with corresponding gene model annotation 
(Homo_sapiens.GRCh38.88.gtf) using the HISAT2 (22). Aligned reads were counted using the 
featureCounts (23) (SDC-2; SDC-3). DEGs were identified by a previously experimentally 
validated (24) edgeR 3.18.1 algorithm employing tag-wise dispersion (25), and Benjamini-
Hochberg genome-wide false discovery rate (FDR) correction (5%). The edgeR algorithm 
calculated p-values by employing exact tests (no df) after fitting gene-specific quasi-negative 
binominal models and estimating dispersion using the quantile adjusted conditional maximum 
likelihood method. The LBD group including both DLB and PDD groups (n=14) was compared 
7 
 
with the NDC group for identifying DEGs in LBD brains. Later, pairwise subgroup analyses 
were conducted with FDR correction. 
Verification of identified DEGs:  
 Differential expression of 78 selected genes (SDC-4) including all protein coding FDR-
adjusted DEGs and 10 randomly selected DEGs (edgeR p<0.05; no df) in DLPFC of LBD 
brains were evaluated using high-throughput quantitative polymerase chain reactions (qPCR). 
One µg of RNA per sample from the aliquots of RNA that had been sequenced (N=40) were 
reverse transcribed using the iScript™ advanced cDNA synthesis kit (Bio-Rad, Hercules, 
USA). After 14 cycles of specific target amplification with the PreAmp master-mix (Fluidigm, 
San Francisco, USA), high-throughput qPCR was performed using the BioMark HD, GE 96.96 
dynamic arrays (Fluidigm, San Francisco, USA), and SsoFast EvaGreen low ROX kit (Bio-
Rad, Hercules, USA) (SDC-5). Verification of differential expression of a gene was defined by 
the following criteria (26), (i) Both RNA-seq and qPCR showed same direction of differential 
expression, (ii) Differential expression fold change, estimated by qPCR, was either above 1.25 
or below 0.80 (logarithmic cut-off was ±0.3219). 
Ingenuity Pathway Analysis (IPA):  
 Functional implications of identified DEGs (edgeR p<0.05; no df) were analyzed by 
the IPA using the Ingenuity knowledge base (Ingenuity, Redwood City, USA). The IPA helps 
identifying potential biomarkers within the context of biological systems. Our analysis settings 
included stringent filters with only experimentally observed relationships, and we identified 
dysfunctional molecular networks in LBD brains.  
Comparison with AD gene expression data:  
 We gathered all AD related gene expression data publicly available in the NCBI GEO 
database (27). A DEG was deemed to be specific to LBD, if the gene either was not altered in 
the AD gene expression profiles, or if it was reportedly altered in the opposite direction. 
8 
 
Brain-specific genome-scale metabolic model (GEM):  
 We used a previously generated brain-specific GEM (28).  The GEM includes 630 
metabolic reactions, controlled by 570 genes, within and between astrocytes and neurons, and 
the metabolites that exchange or transport through the blood-brain barrier. We have modified 
the lactate release from neurons, glycogen accumulation in astrocytes, glutamate cycling, 
GABA transfer direction, and pentose phosphate pathway, and have included the reaction of 
astrocyte lactate shuttle to the GEM based on our transcriptomic data. Glutamate/glutamine 
cycle and ATP demand were considered as objective functions. In order to generate tissue-
specific GEMs, we employed Metabolic Adjustment by Differential Expression (MADE) (29) 
and Toolbox for Integrating Genome scale metabolism, Expression, and Regulation (TIGER) 
(30) using logarithmic fold changes and p-values, obtained from the edgeR (25) analyses, as 
input. Flux balance analysis (FBA) was used as a mathematical constraint-based modelling 
approach for analyzing the flow of metabolites through a metabolic network, and it investigated 
the metabolic reprogramming in LBD brains.  
Reporter metabolite analyses:  
 We further investigated the metabolic reprogramming in LBD brains by reporter 
metabolite analyses using an updated human metabolic reactions model (31), the Platform for 
Integrated Analysis of Omics data (PIANO) (32), and gene-level logarithmic fold changes and 
the p-values, obtained from the edgeR analyses, with the Stouffer’s test (no df) employing a 
permutation (1000) approach. 
In-silico gene silencing:  
 The effects of silencing each of the 570 metabolic genes was simulated using the 
generated GEMs by removing reaction(s) associated with the gene. The reactions were 
retained, if another gene catalyzing the same reaction(s) is present. Then, FBA was performed 
for checking the effects of in-silico gene silencing on the functionality of models. When the 
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gene silencing decreased the flux of objective function, it was considered as an essential gene 
for that condition.  
 
Results: 
DEGs in LBD brains: 
 The LBD (DLB and PDD) and NDC groups did not differ significantly on their 
spectrophotometer mean absorbance ratios in both ACC (260/280 (t=0.74;df=18;p=0.47); 
260/230 (t=-2.02;df=18;p=0.06)) and DLPFC (260/280 (t=0.21;df=18;p=0.84); 260/230 
(t=1.48;df=18;p=0.16)). We identified 1464 upregulated, and 1652 downregulated DEGs 
(edgeR p<0.05; no df) in ACC (SDC-6), and 1233 upregulated and 1414 downregulated DEGs 
(edgeR p<0.05; no df) in DLPFC (SDC-7) of LBD brains, compared to NDC brains. After 
genome-wide FDR correction, we identified 12 protein coding DEGs in LBD brains (Table-1). 
MPO, SELE, CTSG, ALPI, and ABCA13 were significantly downregulated in both ACC and 
DLPFC. GALNT6 was significantly upregulated in DLPFC. RBM3, CSF3, SLC4A1, OXTR, 
and RAB44 were significantly downregulated in ACC, and SST was significantly 
downregulated in DLPFC of LBD brains. Differential expression levels of these 12 DEGs 
could be verified (26) by high-throughput qPCR (Table-1). Moreover, differential expression 
levels of 62.3% (38/61; 95%CI 50.1-74.5%) of other DEGs (edgeR p<0.05; no df) could be 
verified (26) by high-throughput qPCR (SDC-8). Cytokine gene IL1B, chemokine gene 
CXCL11, and neutrophil defensin genes, DEFA3 and DEFA4, were significantly 
downregulated (edgeR p<0.05; no df) in both ACC and DLPFC of LBD brains, and their 
differential expression levels could be verified by qPCR in both cortical regions. The 
statistically significant (edgeR p<0.05; no df) downregulated DEGs in LBD brains, verified by 
high-throughput qPCR, included VGF encoding a nerve growth factor, VCAM1 encoding a 
vascular cell adhesion molecule, and STX11 encoding a syntaxin (Table-2). 
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DEGs in DLB and PDD brains:  
 The subgroup analyses identified 735 upregulated, and 979 downregulated DEGs 
(edgeR p<0.05; no df) in ACC, and 973 upregulated and 1330 downregulated DEGs (edgeR 
p<0.05; no df) in DLPFC of DLB brains, compared to NDC brains (SDC-9). After FDR 
correction, CTSG, and SELE were significantly downregulated, and GIPR, and PSPHP1 were 
significantly upregulated in DLPFC of DLB brains. There was not any FDR-adjusted DEG in 
ACC of DLB brains. When we compared PDD brains with NDC brains, we identified 1764 
upregulated, and 2066 downregulated DEGs (edgeR p<0.05; no df) in ACC, and 1293 
upregulated and 1114 downregulated DEGs (edgeR p<0.05; no df) in DLPFC of PDD brains 
(SDC-10). ADAMTS2 was significantly upregulated, and MPO, and OXTR, were significantly 
downregulated in ACC, as well as GALNT6 was significantly upregulated, and CTSG, SST, and 
OR11H4 were significantly downregulated in DLPFC of PDD brains, compared to NDC, after 
FDR correction (SDC-10). While comparing with PDD brains, there were 1236 downregulated 
and 1043 upregulated DEGs (edgeR p<0.05; no df) in ACC of DLB brains, but none of them 
was significant after FDR correction. We identified 607 upregulated and 987 downregulated 
DEGs (edgeR p<0.05; no df) in DLPFC of DLB brains, compared to PDD brains. DLB could 
be differentiated from PDD by the downregulation of nine FDR-adjusted DEGs including 
PTGER3, and CRABP1 in their DLPFC (SDC-11) (SDC-12).  
Dysfunctional molecular networks:  
 The genes, associated with the agranulocytes adhesion and diapedesis, granulocytes 
adhesion and diapedesis, atherosclerosis signaling, and differential regulation of cytokine 
production in macrophages and T-helper cells by IL-17A and IL-17F pathways, were 
significantly enriched among the DEGs (edgeR p<0.05; no df) in both cortical regions of LBD 
brains after Benjamini-Hochberg FDR correction (Figure-1A&1B). Immune system related 
canonical pathways including IL-6 signaling, systemic lupus erythematosus signaling, 
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communication between innate and adaptive immune cells, and role of cytokines in mediating 
communication between immune cells were significantly enriched among the DEGs in DLPFC 
of LBD brains after FDR correction (Figure-1A). Downregulation of genome-wide significant 
DEGs, CSF3 and SST, and of qPCR-verified DEGs, IL1B and VGF, and their interactions with 
other identified DEGs (edgeR p<0.05; no df) form a molecular network that can impair 
neuronal development, maintenance, survival, and function in DLPFC of LBD brains (Figure-
1C). Furthermore, differential expression of CSF3, and of qPCR-verified DEGs,  IL1B, NOS3, 
VCAM1, and SPP1, and their interactions with other identified DEGs form a molecular network 
that can lead to cell-to-cell signaling, and cellular movement impairment, immune system 
dysfunction, and neurodegeneration in ACC of LBD brains (Figure-1D). 
Comparing with AD gene expression data:  
 We investigated whether the identified DEGs are specific to LBD or they represent a 
non-specific dementia phenotype by reviewing the AD-related gene expression data available 
in the NCBI GEO database (27). Downregulation of RBM3 and SST, and upregulation of 
GALNT6 in LBD were consistent with their differential expression levels, reported by prior 
AD studies. Differential expression levels of at least seven genome-wide significant DEGs 
(SELE, CTSG, ALPI, ABCA13, CSF3, OXTR, and RAB44) in LBD brains were distinct from 
their reported levels in AD brains (SDC-13).  
Metabolic reprogramming in LBD brains:  
 The metabolic changes in the generated constraint-based flux balance LBD models 
(SDC-14) highlighted decreased mitochondrial respiratory chain activity by showing lower 
flux of tricarboxylic acid (TCA) cycle and oxidative phosphorylation for ATP-synthesis than 
those in NDC models. Reactive oxygen species (ROS), associated with neurodegeneration, 
were excessively produced in LBD reprogramed models. The glutathione peroxidase activity 
for scavenging ROS also was increased in the LBD reprogramed models, and the increased 
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flux for redox responses in LBD was dependent on NADPH-dependent hydrogen peroxide 
scavenging, catalyzed by isocitrate dehydrogenase (IDH) (Figure-2).  IDH deficiency induces 
sensitivity to oxidative stress that leads to neurodegeneration (33), and the LBD reprogramed 
models showed high sensitivity to in-silico gene silencing of IDH1 and IDH2. Moreover, the 
GEM demonstrated the importance of astrocytes releasing glutathione precursors. When we 
blocked astrocytes dependent reactions in the LBD models, the neurons could not handle the 
oxidative stress. Furthermore, we identified 84 reporter metabolites that displayed FDR-
adjusted statistically significant changes in LBD brains (SDC-15). The downregulated reporter 
metabolites included those related to TCA cycle, such as malate, α-ketoglutarate, acetyl-CoA, 
NAD(H), acetate, glutamate, ubiquinone, estradiols, isobutyryl-CoA, and homocysteine, and 
several metabolites involved in fatty acids and lipid metabolism (SDC-14). These findings 
corroborated the lower flux of TCA cycle, and mitochondrial dysfunction in LBD brains 
(Figure-2).  
 
Discussion: 
 Notwithstanding its small sample size, this is the hitherto largest RNA-Seq study 
investigating transcriptomics of LBD brains (13-15). Moreover, this is the first study evaluating 
the transcriptomic differences between DLB and PDD, and integrating LBD transcriptomic 
data into genome-scale metabolic modelling. We have identified 12 novel genome-wide 
significant DEGs, distinct from known genetic markers of AD and PD, in LBD brains, and 
have verified them using high-throughput qPCR. We identified specific dysfunctional 
molecular networks in LBD brains, and have added evidence for mitochondrial dysfunction 
and immunosenescence in LBD. The identified DEG, and their dysfunctional molecular 
networks advance molecular level mechanistic understanding of neurodegeneration in LBD, 
and they can facilitate identifying potential diagnostic biomarkers for LBD. Nevertheless, the 
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limitations of this study include its small sample size comprising mostly men, the lack of AD 
and PD comparison groups, not investigating cerebellum that does not typically have 
substantial α-synuclein pathology, and the lack of data on the use of dopaminergic medications. 
 Our GEM analyses have demonstrated how mitochondrial dysfunction and oxidative 
stress contribute towards neurodegeneration in LBD. Mitochondrial dysfunction can set off a 
vicious cycle by producing more ROS that lead to more mitochondrial oxidative damage (34). 
Consequent oxidative stress may lead to α-synuclein oligomerization worsening the vicious 
cycle by damaging more mitochondria (34). Oxidative stress has bidirectional causal 
relationship with hypoxia, and sustained hypoxia can lead to anti-inflammatory response in 
LBD brains (35). Moreover, the GEM demonstrated how astrocytes help neurons to cope with 
oxidative stress by releasing glutathione precursors. Hence, astrocytes dysfunction may 
contribute to neurodegeneration in LBD. Additionally, our findings indicate the need for 
further studies investigating IDH that catalyzes NADPH-dependent hydrogen peroxide 
scavenging as a potential therapeutic target that may modify the vicious cycle and the disease 
process. 
 Our results showed that the neuroimmunological profile of LBD brains differ widely 
from chronic neuroinflammation in AD (16). Prior evidence indicating neuroinflammation in 
LBD are weak, and they were principally derived from increased CD68 immunostaining that 
can be explained by impaired proteostasis and microglial dystrophy (17,18,36). 
Immunohistochemical staining with IBA1 and CD68 antibodies has demonstrated low 
microglia density, and increased microglial dystrophy in LBD brains (18). A recent 
transcriptomic and proteomic study has reported lack of evidence for microglia mediated 
neuroinflammation in post-mortem pulvinar of people with LBD (36). We have documented 
statistically significant downregulation of several cytokine and chemokine genes including 
IL1B, IL2, IL6, CXCL2, CXCL3, CXCL8, CXCL10, and CXCL11. Downregulation of MPO, 
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and of vascular cell adhesion molecules encoding SELE and VCAM1 add evidence for the 
absence of neuroinflammation in LBD brains. Optimal microglial activation is essential for 
neuronal survival, and the importance of neuroprotective and synaptic modulatory functions of 
microglia in adult brain is increasingly recognized (37). Hence, immune dysfunction leading 
to impaired neuronal protection and survival rather than chronic neuroinflammation may 
explain neuronal loss in LBD. The differential expression levels of these inflammatory markers 
and of the associated molecules may distinguish LBD from AD, and further research 
investigating their biomarker potential are warranted.  
 Neutrophil extravasation has been associated with AD pathology (38), but little is 
known about its role in LBD. We have verified downregulation of neutrophil defensin genes, 
and have highlighted the dysfunctional granulocyte adhesion and diapedesis pathway in LBD 
brains. CTSG encoding a neutrophil serine protease, Cathepsin G, was significantly 
downregulated in both cortical regions of LBD brains. Cathepsin G influences the permeability 
of blood brain barrier, and its downregulation can contribute to impaired proteostasis and 
neurodegeneration in LBD (39). Moreover, Granulocyte colony stimulating factor (GCSF), 
coded by CSF3, stimulates the proliferation and survival of neutrophils and it is a neurotrophic 
factor (40). GCSF may facilitate neuroplasticity, and can inhibit apoptosis (41). We have 
documented CSF3 downregulation in LBD brains, and have highlighted the importance of 
CSF3 associated molecular networks hindering neuronal survival, and leading to immune 
dysfunction, and neurodegeneration in LBD. Serum GCSF levels were significantly less in 
people with AD than cognitively-intact controls (41), and a pilot study has demonstrated the 
safety of GCSF in people with AD (42). However, the biomarker and therapeutic potential of 
GCSF has not been systematically evaluated in LBD so far.  
 MPO polymorphisms have been associated with sporadic and familial forms of AD. 
Myeloperoxidase co-localizes with β-amyloid deposits in AD brains (43), and increased plasma 
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myeloperoxidase levels have been reported in people with AD (44). As we documented 
significantly reduced MPO expression in LBD, peripheral biomarker potential of 
myeloperoxidase and its mRNA in people with LBD warrant further investigation. Moreover, 
synaptic loss leads to neurodegeneration, and downregulation of RBM3 reportedly leads to 
synaptic loss in mice (45). RBM3 modulates synaptic plasticity, and it can be a potential 
therapeutic target for LBD. Besides, our results rekindle the interest on somatostatinergic 
systems. Loss of somatostatin expressing interneurons (46), and consequent impairment of 
microglial migration and their target-specific phagocytosis (47) may contribute to cognitive 
impairment in LBD. Furthermore, downregulation of VGF may compromise neuronal survival 
and energy homeostasis in LBD brains. Increased expression of VGF in cerebrospinal fluid 
and peripheral lymphocytes has been detected in AD (48), but the biomarker potential of VGF 
has not been investigated in LBD. 
 As advanced stages of DLB and PDD are often clinically indistinguishable, the 
nosological validity and diagnostic boundaries of these disorders are continuously debated 
(49). We have documented the molecular differences between DLB and PDD, and more 
pronounced transcriptomic differences at earlier clinical stages can be hypothesized. Predicting 
early stage transcriptomic differences and their longitudinal changes from the findings of post-
mortem brain studies are difficult. However, circulating exosomes transporting RNA between 
brain and peripheral systems provide an opportunity for studying the molecular changes in 
living human brain (50). Hence, we are currently investigating serum and cerebrospinal fluid 
exosomal RNA profiles for understanding the molecular changes in LBD over its disease 
course, and for evaluating the biomarker potential of identified DEGs. 
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Figure-legends: 
Figure-1: Functional analyses of identified differentially expressed genes in post-mortem 
brains of people with Lewy body dementias 
A: Canonical pathways that were enriched among the statistically significant (edgeR p<0.05; 
no df) differentially expressed genes (DEGs) in dorsolateral prefrontal cortices (DLPFC) of 
people with Lewy body dementias (LBD); B: Canonical pathways that were enriched among 
the statistically significant (edgeR p<0.05; no df) DEGs in anterior cingulate cortices (ACC) 
of people with LBD; (A&B) Green represents downregulated genes, and red represents 
upregulated genes. Yellow line presents the p-values after Benjamini-Hochberg false discovery 
rate (5%) correction. 
C: A network of DEGs in DLPFC of people with LBD may impair neuronal development, 
maintenance, and survival; D: A network of DEGs in ACC of people with LBD may lead to 
cell-to-cell signaling impairment, and immune system dysfunction; (C&D) Green represents 
downregulated genes, and red represents upregulated genes. Solid lines represent direct 
interactions and dotted lines represent indirect interactions. 
Figure-2: Flux balance analysis, performed on brain-specific genome scale metabolic models, 
highlighted the metabolic changes in LBD brains  
The flux of reactions related to oxidative stress response increase in LBD. Scavenging of 
hydrogen peroxide (H2O2) is done by glutathione peroxidase. Astrocytes release the precursors 
of Glutathione (GSH). The increased flux for Redox responses to hypoxia in LBD is related to 
NADPH-dependent H2O2 scavenging, catalyzed by isocitrate dehydrogenase (IDH), 
supporting the system through the NADPH production. Additionally, the activity of 
tricarboxylic acid cycle and mitochondrial respiratory chain are reduced in LBD. aKG: alpha 
ketoglutarate, GSH: Reduced Glutathione and GSSG: Oxidized Glutathione. 
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Supplemental digital content (SDC): 
1. SDC-1 presents the diagnosis, age, gender, post-mortem interval, and co-existent AD 
pathology of the brains that have been included in this study (.docx file). 
2. SDC-2 presents the expression count matrix of RNA-seq data from post-mortem anterior 
cingulate cortices (.xlsx file).  
3. SDC-3 presents the expression count matrix of RNA-seq data from post-mortem 
dorsolateral prefrontal cortices (.xlsx file).  
4. SDC-4 presents forward and reverse primer sequences that have been used for high-
throughput qPCR replication of 78 selected genes (first worksheet) and 7 reference (second 
worksheet) genes. It has two worksheets. (.xlsx file).  
5. SDC-5 presents an overview of RNA extraction, cDNA synthesis, specific target 
amplification and high-throughput qPCR replication procedures (.docx file) 
6. SDC-6 presents differential expression analyses of RNA-seq data from post-mortem 
anterior cingulate cortices of 13 Lewy body dementias, and 7 control brains without 
dementia and Parkinson’s disease (.xlsx file). 
7. SDC-7 presents differential expression analyses of RNA-seq data from post-mortem 
dorsolateral prefrontal cortices of 14 Lewy body dementias, and 6 control brains without 
dementia and Parkinson’s disease (.xlsx file). 
8. SDC-8 presents the results of high-throughput qPCR verification. It has two worksheets. 
First worksheet presents the results from anterior cingulate cortices, and the second 
worksheet presents the results from dorsolateral prefrontal cortices (.xlsx file). 
9. SDC-9 presents differential expression analyses comparing post-mortem dementia with 
Lewy bodies and control brains without dementia and Parkinson’s disease. It has two 
worksheets. First worksheet presents the results from anterior cingulate cortices, and the 
second worksheet presents the results from dorsolateral prefrontal cortices (.xlsx file). 
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10. SDC-10 presents differential expression analyses comparing post-mortem Parkinson’s 
disease dementia and control brains without dementia and Parkinson’s disease. It has two 
worksheets. First worksheet presents the results from anterior cingulate cortices, and the 
second worksheet presents the results from dorsolateral prefrontal cortices (.xlsx file). 
11. SDC-11 presents differential expression analyses comparing post-mortem Parkinson’s 
disease dementia and dementia with Lewy bodies brains. It has two worksheets. First 
worksheet presents the results from anterior cingulate cortices, and the second worksheet 
presents the results from dorsolateral prefrontal cortices (.xlsx file). 
12. SDC-12 presents differential expression analyses comparing Lewy body dementia brains 
with minimal or no co-existing Alzheimer's disease pathology (All ABC scores ≤ 1) and 
Lewy body dementia brains with more co-existing Alzheimer's disease pathology (at least 
one of the ABC scores ≥ 2). It has two worksheets. First worksheet presents the results from 
anterior cingulate cortices, and the second worksheet presents the results from dorsolateral 
prefrontal cortices (.xlsx file). 
13. SDC-13 presents differential expression fold changes, estimated by meta-analyses of prior 
gene expression studies investigating post-mortem Alzheimer's disease brains, of 26 
selected differentially expressed genes in LBD (.xlsx file). 
14.  SDC-14 presents the flux balance analysis investigating the metabolic reprogramming in 
brains of people with Lewy body dementias.  First worksheet presents the results from 
anterior cingulate cortices, and the second worksheet presents the results from dorsolateral 
prefrontal cortices (.xlsx file). 
15. SDC-15 presents the reporter metabolite analysis investigating the metabolic 
reprogramming in brains of people with Lewy body dementias. It has six worksheets.  The 
first three worksheets present the results from anterior cingulate cortices, and the next three 
worksheets present the results from dorsolateral prefrontal cortices (.xlsx file). 
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Table 1: 12 genome-wide significant differentially expressed genesa in post-mortem brains of people with Lewy body dementias 
Gene  Gene name LFC b qPCR LFC p c q d 
MPO myeloperoxidase -4.49 -3.58 5.43E-11 3.07E-06 
SELE selectin E -3.64 -2.47 2.90E-09 8.19E-05 
ABCA13 ATP binding cassette subfamily A member 13 -3.63 -2.36 8.85E-08 0.0017 
ALPI alkaline phosphatase, intestinal -6.69 -1.17 4.36E-07 0.0054 
SLC4A1 solute carrier family 4 member 1 -2.61 -1.55 4.80E-07 0.0054 
OXTR oxytocin receptor -1.08 -0.94 6.93E-07 0.0065 
CSF3 colony stimulating factor 3 -4.14 -5.57 9.06E-07 0.0073 
CTSG cathepsin G -6.75 -7.61 4.56E-06 0.0286 
RAB44 RAB44, member RAS oncogene family -3.88 -1.92 4.26E-06 0.0286 
RBM3 RNA binding motif protein 3 -1.03 -2.17 5.74E-06 0.0303 
GALNT6 polypeptide N-acetylgalactosaminyltransferase 6 1.35e 0.95e 4.33E-07 0.0049 
SST somatostatin -2.27e -1.61e 8.89E-07 0.0072 
 
a Differentially expressed genes that were identified by RNA-seq and were verified by high-throughput quantitative polymerase chain reaction 
(qPCR); b Logarithmic (base 2) fold change, measured by RNA-seq; c RNA-seq p value that was estimated using the edgeR algorithm. The edgeR 
algorithm employed exact tests (no df) for calculating p-values after fitting gene-specific quasi-negative binominal models and estimating 
dispersion using the quantile adjusted conditional maximum likelihood method; d RNA-seq q value after Benjamini-Hochberg false discovery rate 
(5%) correction; e in dorsolateral prefrontal cortex. 
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Table 2: Other verified differentially expressed genes a in post-mortem brains of people with Lewy body dementias 
Anterior Cingulate Cortex Dorsolateral Prefrontal Cortex 
Gene LFC b qPCR LFC p c q d Gene LFC b qPCR LFC p c q d 
ADAMTS2 1.05 1.23 1.15E-05 0.0521 CXCL11 -3.72 -2.35 1.14E-05 0.0682 
UTF1 -3.73 -1.53 1.22E-05 0.0521 VGF -1.79 -0.79 4.73E-05 0.2058 
DEFA4 -6.15 -2.37 2.91E-05 0.0897 ADAMTS2 1.02 2.15 0.0001 0.3372 
CXCL11 -3.19 -1.91 7.43E-05 0.1399 LDHC 4.16 5.49 0.0002 0.4165 
XIST 8.56 1.43 0.0002 0.2581 GIPR 2.30 1.18 0.0004 0.4165 
DEFA3 -5.34 -2.64 0.0004 0.3266 XIST 8.75 1.83 0.0006 0.4652 
GBP6 -1.18 -2.52 0.0013 0.4438 ADRA2B 1.48 -0.86 0.0009 0.5467 
STX11 -1.24 -1.03 0.0015 0.4701 DEFA4 -4.95 -3.91 0.0010 0.5467 
GRK7 1.64 2.01 0.0015 0.4725 GBP6 -1.42 -1.30 0.0015 0.6017 
GIPR 1.60 0.84 0.0020 0.4911 REG4 -4.15 -1.19 0.0019 0.6017 
ABCD2 -0.59 -0.70 0.0020 0.4911 SBSN 1.84 0.39 0.0036 0.7670 
IL1B -1.68 -1.49 0.0050 0.6213 DEFA3 -3.77 -2.62 0.0076 0.8123 
SPP1 1.40 0.95 0.0053 0.6213 SPP1 0.96 0.80 0.0102 0.8329 
VCAM1 -1.18 -1.32 0.0124 0.7229 IL1B -1.41 -1.01 0.0103 0.8335 
VGF -0.91 -2.64 0.0230 0.7684 CPA3 -3.77 -2.17 0.0142 0.8849 
CP -0.93 -1.12 0.0257 0.7764 GRK7 1.24 1.97 0.0201 0.9649 
CRABP1 1.57 0.78 0.0265 0.7767 WISP1 1.11 1.11 0.0275 1.0000 
LDHC 2.37 2.78 0.0395 0.8274 CP -0.91 -1.34 0.0277 1.0000 
NOS3 -1.08 -1.20 0.0454 0.8274 GPR50 -2.04 -1.93 0.0412 1.0000 
OR11H4 -1.26 -1.35 0.0471 0.8274 ABCD2 -0.43 -0.57 0.0463 1.0000 
a Differentially expressed genes that were identified by RNA-seq and were verified by high-throughput qPCR; b Logarithmic (base 2) fold change, 
measured by RNA-seq; c RNA-seq p value that was estimated using edgeR algorithm. The edgeR algorithm employed exact tests (no df) for 
calculating p-values after fitting gene-specific quasi-negative binominal models and estimating dispersion using the quantile adjusted conditional 
maximum likelihood method; d RNA-seq q value after Benjamini-Hochberg false discovery rate (5%) correction. 
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